Taisho Pharmaceutical Holdings Co., Ltd.
TSE:4581.T
8580 (JPY) • At close April 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 301,381 | 268,203 | 282,037 | 288,720 | 261,369 | 280,138 | 279,750 | 289,956 | 290,489 | 295,969 | 285,114 | 271,245 | 268,698 | 258,518 | 256,351 | 249,783 | 242,075 | 271,129 |
Cost of Revenue
| 123,531 | 104,371 | 106,050 | 108,337 | 91,206 | 97,154 | 101,525 | 113,143 | 112,240 | 111,275 | 108,904 | 98,998 | 96,460 | 91,815 | 86,889 | 85,295 | 82,224 | 86,408 |
Gross Profit
| 177,850 | 163,832 | 175,987 | 180,383 | 170,163 | 182,984 | 178,225 | 176,813 | 178,249 | 184,694 | 176,210 | 172,247 | 172,238 | 166,703 | 169,462 | 164,488 | 159,851 | 184,721 |
Gross Profit Ratio
| 0.59 | 0.611 | 0.624 | 0.625 | 0.651 | 0.653 | 0.637 | 0.61 | 0.614 | 0.624 | 0.618 | 0.635 | 0.641 | 0.645 | 0.661 | 0.659 | 0.66 | 0.681 |
Reseach & Development Expenses
| 20,727 | 19,366 | 20,251 | 22,876 | 20,801 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24,745 | 28,519 | 23,072 |
General & Administrative Expenses
| 84,648 | 82,318 | 78,376 | 74,492 | 63,123 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 131,526 | 14,942 | 13,083 | 13,906 |
Selling & Marketing Expenses
| 49,456 | 51,404 | 57,394 | 61,555 | 55,027 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39,096 | 42,301 | 44,724 |
SG&A
| 134,104 | 133,722 | 135,770 | 136,047 | 118,150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 131,526 | 54,038 | 55,384 | 58,630 |
Other Expenses
| 322 | -136 | 335 | 170 | 1,103 | 634 | 606 | 686 | 658 | 591 | 819 | 1,482 | 1,245 | 877 | 2,100 | 822 | 736 | 162 |
Operating Expenses
| 154,831 | 153,088 | 156,021 | 158,923 | 138,951 | 146,007 | 146,260 | 147,935 | 146,273 | 143,009 | 140,873 | 133,833 | 128,154 | 132,017 | 131,526 | 118,666 | 127,153 | 126,303 |
Operating Income
| 23,018 | 10,743 | 19,965 | 21,460 | 31,211 | 36,977 | 31,966 | 28,878 | 31,974 | 41,683 | 35,337 | 38,414 | 44,084 | 34,686 | 37,936 | 45,822 | 32,698 | 58,418 |
Operating Income Ratio
| 0.076 | 0.04 | 0.071 | 0.074 | 0.119 | 0.132 | 0.114 | 0.1 | 0.11 | 0.141 | 0.124 | 0.142 | 0.164 | 0.134 | 0.148 | 0.183 | 0.135 | 0.215 |
Total Other Income Expenses Net
| 6,479 | 10,654 | 3,010 | 8,850 | 33,270 | 11,093 | 9,990 | 6,931 | 8,187 | 9,632 | 7,871 | 4,578 | 8,922 | 1,104 | -11,177 | -4,832 | -3,702 | -107 |
Income Before Tax
| 29,498 | 21,398 | 22,976 | 30,311 | 64,484 | 48,070 | 41,956 | 35,809 | 40,162 | 51,316 | 43,208 | 42,992 | 53,006 | 35,790 | 26,759 | 40,990 | 28,996 | 58,311 |
Income Before Tax Ratio
| 0.098 | 0.08 | 0.081 | 0.105 | 0.247 | 0.172 | 0.15 | 0.123 | 0.138 | 0.173 | 0.152 | 0.158 | 0.197 | 0.138 | 0.104 | 0.164 | 0.12 | 0.215 |
Income Tax Expense
| 8,196 | 6,448 | 7,782 | 8,423 | 14,658 | 14,701 | 11,750 | 11,927 | 14,102 | 17,305 | 15,630 | 17,740 | 17,212 | 15,180 | 16,818 | 15,782 | 13,795 | 22,517 |
Net Income
| 18,997 | 13,122 | 13,316 | 20,172 | 48,593 | 31,679 | 28,781 | 22,473 | 24,528 | 32,692 | 26,320 | 24,357 | 34,892 | 19,485 | 8,815 | 25,004 | 15,420 | 35,884 |
Net Income Ratio
| 0.063 | 0.049 | 0.047 | 0.07 | 0.186 | 0.113 | 0.103 | 0.078 | 0.084 | 0.11 | 0.092 | 0.09 | 0.13 | 0.075 | 0.034 | 0.1 | 0.064 | 0.132 |
EPS
| 231.72 | 161.12 | 166.83 | 252.73 | 608.8 | 396.54 | 360.18 | 277.75 | 302.57 | 403.18 | 325.26 | 296.2 | 416.33 | 226.6 | 100.03 | 280.03 | 168.47 | 387.27 |
EPS Diluted
| 231.42 | 160.93 | 166.63 | 252.44 | 608.22 | 396.2 | 359.92 | 277.59 | 302.42 | 403.07 | 325.22 | 296.2 | 416.33 | 226.6 | 100.03 | 280.03 | 168.47 | 387.27 |
EBITDA
| 55,286 | 41,656 | 48,192 | 41,824 | 52,141 | 53,523 | 49,707 | 49,249 | 52,515 | 63,634 | 56,243 | 58,289 | 66,540 | 48,512 | 64,542 | 63,396 | 48,521 | 83,096 |
EBITDA Ratio
| 0.183 | 0.155 | 0.171 | 0.145 | 0.199 | 0.191 | 0.178 | 0.17 | 0.181 | 0.215 | 0.197 | 0.215 | 0.248 | 0.188 | 0.252 | 0.254 | 0.2 | 0.306 |